how does tirzepatide differ from semaglutide vs. for Obesity Comparing Tirzepatide vs Semaglutide: Effects,

After matching 168,428 patients in each group, GLP-1 receptor agonist users had a VTE rate of 11.0 per 1,000 patient-years compared to 12.9 per 1,000 patient-years in those taking DPP-4 inhibitors (a different class of diabetes medication)

Sustained loss with improved glucose and metabolic markers was reported

However, around the time that bariatric surgerys positive effects on diabetes and cardiovascular outcomes were emerging from observational studies, researchers were taking note of the weight-loss and cardiovascular effects of the GLP-1 receptor agonist medications (GLP-1 RAs) used to treat type 2 diabetes

Metabolic Changes Clinical studies may monitor blood sugar, insulin response, cholesterol, and other metabolic measurements